P1 Trials, Inc.

P1 Trials, founded in 2024 in Seattle, Washington, specializes in Phase 1 oncology clinical trials, focusing on evaluating the safety and pharmacokinetics of new cancer therapies. P1 Trials, Inc. is dedicated to conducting Phase 1 clinical trials for oncology, assessing new therapeutic agents. The company was established in 2024 in Seattle, Washington, and has successfully completed one deal as of November 1, 2024.

The firm raised USD 1. 65 mn in its latest funding round, which is the total amount raised to date. Details about the founder’s previous ventures are not available. P1 Trials specializes in conducting Phase 1 oncology clinical trials designed to evaluate the safety, tolerability, and pharmacokinetics of new therapeutic agents for cancer treatment.

The company's primary offerings focus on providing comprehensive trial management solutions to facilitate the transition of experimental drugs from the laboratory to clinical application. Their end-use cases revolve around addressing unmet medical needs in oncology, particularly for patients with advanced or refractory cancers seeking innovative treatment options. P1 Trials serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and research institutions engaged in drug development. Their services are primarily targeted at markets in North America, Europe, and Asia, where there is a robust demand for clinical research in oncology.

Revenue generation for P1 Trials typically occurs through contractual agreements with pharmaceutical and biotechnology companies that sponsor clinical trials. These transactions are structured as service agreements, where clients fund trial operations in exchange for comprehensive data on drug efficacy and safety. Flagship services include patient recruitment, data management, and regulatory compliance assistance. The company may also engage in partnerships with research institutions, generating additional revenue streams through collaborative research initiatives.

Overall, the firm positions itself within a B2B framework, directly serving industry partners seeking to advance their oncology portfolios. In November 2024, P1 Trials, Inc. secured USD 1. 65 mn in venture funding from an unspecified investor.

This funding will support the development of new oncology therapies, with plans to launch additional products focused on addressing specific cancer types. The company aims to expand its operations into new markets, particularly targeting Europe and Asia by the end of 2025, where there is increasing demand for clinical trials in oncology.